Literature DB >> 8890437

Postsurgical hypotony: relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous.

H D Schubert1.   

Abstract

Hypotony is a natural occurrence, symptom, and complication of surgical treatment. With more sophisticated and aggressive techniques, postsurgical hypotony recently has been given increased attention as an obstacle to success of surgery for glaucoma and retinal detachment. Whereas two standard deviations below normal pressure (15.9-5.8 = 10.1 mm Hg) can be called hypotonous, most eyes, depending on scleral rigidity, lid pressure, eye rubbing, or corneal or retinal edema, will be symptomatic at < 5 mm Hg. Hypotony can be defined as the low pressure (whether acute, transient, chronic or permanent) which, in an individual eye, leads to functional changes (whether asymptomatic or symptomatic) and structural changes (whether reversible or irreversible). Depending on its duration and degree, postsurgical hypotony produces characteristic tissue changes that often are modified by, but separate from, the tissue changes caused by an underlying disease or its surgical treatment. This review summarizes the situations, variably associated with hypotony, that occur after such interventions as cataract extraction, filtering surgery, cyclodialysis, cyclodestruction, and vitreoretinal surgery, in addition to the reported pathomechanisms of hypotony and its proposed treatments.

Entities:  

Mesh:

Year:  1996        PMID: 8890437     DOI: 10.1016/s0039-6257(96)80001-4

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  33 in total

1.  Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Authors:  H Nida Sen; Lea T Drye; Debra A Goldstein; Theresa A Larson; Pauline T Merrill; Peter R Pavan; John D Sheppard; Alyce Burke; Sunil K Srivastava; Douglas A Jabs
Journal:  Ocul Immunol Inflamm       Date:  2012-04       Impact factor: 3.070

2.  Is intraocular pressure the only important postoperative variable? The role of first day postoperative review after vitrectomy.

Authors:  K B Harshey; R Madhukumar
Journal:  Eye (Lond)       Date:  2016-02-05       Impact factor: 3.775

Review 3.  Chorioretinal folds: a proposed diagnostic algorithm.

Authors:  Alessandro Bagnis; Carlo Alberto Cutolo; Guido Corallo; Donatella Musetti; Massimo Nicolò; Carlo Enrico Traverso
Journal:  Int Ophthalmol       Date:  2019-02-20       Impact factor: 2.031

4.  Corneal ectasia associated with postoperative hypotony.

Authors:  Kai B Kang; Elmer Y Tu; Ahmad A Aref; Jacob T Wilensky; Thasarat S Vajaranant
Journal:  Can J Ophthalmol       Date:  2018-06-05       Impact factor: 1.882

5.  Clinical study on Hypotony following blunt ocular trauma.

Authors:  Chun Ding; Jun Zeng
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

6.  Multiple retinal hemorrhage following anterior chamber paracentesis in uveitic glaucoma.

Authors:  Sang Joon Lee; Jung Joo Lee; Shin Dong Kim
Journal:  Korean J Ophthalmol       Date:  2006-06

7.  Relaxing retinotomies and retinectomies in the management of retinal detachment with severe proliferative vitreoretinopathy (PVR).

Authors:  Khaled Ag Shalaby
Journal:  Clin Ophthalmol       Date:  2010-10-05

8.  Three-dimensional high-speed optical coherence tomography for diagnosis of hypotony maculopathy after glaucoma filtration surgery.

Authors:  Margot L Goodkin; Dilraj S Grewal; David S Greenfield
Journal:  J Glaucoma       Date:  2010-08       Impact factor: 2.503

9.  Treating uveitis-associated hypotony with pars plana vitrectomy and silicone oil injection.

Authors:  Rashmi Kapur; Andrea D Birnbaum; Debra A Goldstein; Howard H Tessler; Michael J Shapiro; Lawrence J Ulanski; Michael P Blair
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

10.  Bleb revision for resolution of hypotony maculopathy following primary trabeculectomy.

Authors:  Elena Bitrian; Brian J Song; Joseph Caprioli
Journal:  Am J Ophthalmol       Date:  2014-05-27       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.